Selected article for: "clinical practice and direct method"

Author: Horiuchi, Sho; Saito, Yuichi; Matsui, Atsuka; Takahashi, Nobumasa; Ikeya, Tomohiko; Hoshi, Eishin; Shimizu, Yoshihiko; Yasuda, Masanori
Title: A novel loop-mediated isothermal amplification method for efficient and robust detection of EGFR mutations
  • Document date: 2020_1_14
  • ID: 4sltubqk_2
    Snippet: Previously, direct DNA sequencing was the standard method for detecting genetic mutations (10) ; however, at present, several alternative methods for mutation testing have been developed (11, 12) . For example, the Therascreen EGFR PCR kit ® (Qiagen, Inc.) is a commercial quantitative (q)PCR kit and has been widely adopted for clinical practice; however, this method is time-consuming and possesses certain procedural complexities, for example, re.....
    Document: Previously, direct DNA sequencing was the standard method for detecting genetic mutations (10) ; however, at present, several alternative methods for mutation testing have been developed (11, 12) . For example, the Therascreen EGFR PCR kit ® (Qiagen, Inc.) is a commercial quantitative (q)PCR kit and has been widely adopted for clinical practice; however, this method is time-consuming and possesses certain procedural complexities, for example, requiring several temperature changes during DNA amplification (11) . Next-generation sequencing has improved the efficiency of oncogene testing by high-throughput sequencing, which can detect dozen of mutations at the same time, but the high-cost of this technique limits its clinical usage (13, 14) . Therefore, detecting oncogenic mutations using a simple, easy and highly reproducible method remains a challenge.

    Search related documents:
    Co phrase search for related documents
    • alternative method and commercial quantitative: 1
    • alternative method and dna amplification: 1, 2
    • alternative method and dna sequencing: 1
    • alternative method and generation sequencing: 1, 2
    • alternative method and genetic mutation: 1
    • alternative method and high throughput: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • alternative method and high throughput sequencing: 1, 2, 3, 4, 5
    • challenge remain and generation sequencing: 1
    • challenge remain and genetic mutation: 1
    • challenge remain and high throughput: 1
    • clinical practice and dna amplification: 1
    • clinical practice and dna sequencing: 1, 2, 3
    • clinical practice and generation sequencing: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • clinical practice and high throughput: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • clinical practice and high throughput sequencing: 1, 2, 3, 4, 5, 6
    • commercial quantitative and high throughput: 1, 2, 3
    • commercial quantitative and kit commercial quantitative: 1, 2, 3, 4
    • direct dna sequencing and dna sequencing: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • direct dna sequencing and generation sequencing: 1, 2